ALK and non-small cell lung carcinoma: Ceritinib, an ALK-TKI, was approved for ALK+ metastatic NSCLC with crizotinib intolerance, based on the results of a 2014 trial that included 163 patients [96], and was established as a first-line treatment for ALK+ metastatic NSCLC in 2017 based on a phase III trial [97], conducted by the U.S. FDA (recommended dosage = 750 mg orally once daily) [98].